Editas Medicine logo

Editas MedicineNASDAQ: EDIT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 February 2016

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$241.66 M
-91%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-78%vs. 3y high
42%vs. sector
-96%vs. 3y high
52%vs. sector

Price

regular market | 1 min ago
$2.93-$0.01(-0.34%)

Dividend

No data over the past 3 years
$513.00 K$2.24 M
$513.00 K-$67.61 M

Analysts recommendations

Institutional Ownership

EDIT Latest News

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
zacks.com04 November 2024 Sentiment: -

Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago.

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline
zacks.com25 October 2024 Sentiment: NEGATIVE

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
zacks.com23 October 2024 Sentiment: NEGATIVE

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
seekingalpha.com22 October 2024 Sentiment: POSITIVE

Editas Medicine, Inc. (NASDAQ:EDIT ) Strategic Update Conference Call October 22, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - Chief Executive Officer Linda Burkly - Chief Scientific Officer Erick Lucera - Chief Financial Officer Baisong Mei - Chief Medical Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Samantha Semenkow - Citi Gena Wang - Barclays Jack Allen - Baird Yanan Zhu - Wells Fargo Soumit Roy - Jones Brian Cheng - JPMorgan Chase Joon Lee - Truist Dae Gon Ha - Stifel Alec Stranahan - Bank of America Rick Bienkowski - Cantor Phil Nadeau - TD Cowen Liisa Bayko - Evercore Mani Foroohar - Leerink Partners Timur Ivannikov - Raymond James Operator Good morning, everyone, and thank you for joining Editas Medicine's Strategic Update Webinar. This webinar is being recorded and can be accessed in the future through this same link or through the Investor section of the company's website.

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
zacks.com22 October 2024 Sentiment: POSITIVE

Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
globenewswire.com21 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine's CRISPR Cas12a genome editing systems with Genevant's proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas' upregulation strategy.

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
globenewswire.com18 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m.

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations
gurufocus.com07 October 2024 Sentiment: NEGATIVE

Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%.

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)
seekingalpha.com01 October 2024 Sentiment: NEUTRAL

Editas Medicine, Inc. (NASDAQ:EDIT ) Chardan's 8th Annual Genetic Medicines Conference October 1, 2024 3:45 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - VP Corporate Communications and IR Conference Call Participants Geulah Livshits - Chardan Geulah Livshits I'm Geulah Livshits, a biotech analyst at Chardan and it's my pleasure to introduce Erick Lucera, our CFO; and Cristi Barnett, VP Corporate Communications and IR at Editas. Thank you both for joining us today.

Editas Medicine: A Risk/Reward Worth Considering
seekingalpha.com25 September 2024 Sentiment: POSITIVE

Editas Medicine has made significant progress in advancing reni-cel, their in-vivo editing pipeline, and business development, despite a 65% drop in stock price. Reni-cel shows promising clinical results for sickle cell disease and beta-thalassemia, with potential BLA submission by year-end, enhancing its risk-reward profile. Editas' in-vivo pipeline and strategic partnerships bolster its position, but competition and regulatory challenges remain significant risks.

What type of business is Editas Medicine?

Editas Medicine, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, developing treatment methods based on CRISPR-Cas9 gene editing technology. Editas Medicine, Inc. was founded in 2013. Editas Medicine is a leading genome editing company at the clinical stage, working on the development of potentially transformative genomic medicines for a wide range of serious diseases. The company has developed its own genome editing platform based on CRISPR technology. Editas Medicine's main developments are in the field of eye diseases and engineered cell therapies for the treatment of hemoglobinopathies and cancer.

What sector is Editas Medicine in?

Editas Medicine is in the Healthcare sector

What industry is Editas Medicine in?

Editas Medicine is in the Biotechnology industry

What country is Editas Medicine from?

Editas Medicine is headquartered in United States

When did Editas Medicine go public?

Editas Medicine initial public offering (IPO) was on 03 February 2016

What is Editas Medicine website?

https://www.editasmedicine.com

Is Editas Medicine in the S&P 500?

No, Editas Medicine is not included in the S&P 500 index

Is Editas Medicine in the NASDAQ 100?

No, Editas Medicine is not included in the NASDAQ 100 index

Is Editas Medicine in the Dow Jones?

No, Editas Medicine is not included in the Dow Jones index

When was Editas Medicine the previous earnings report?

No data

When does Editas Medicine earnings report?

The next expected earnings date for Editas Medicine is 08 November 2024